Impaired Hepatic Function Clinical Trial
Official title:
A Phase I, Open Label, Multi-center, Parallel Cohort, Single Dose Study to Evaluate the Pharmacokinetics of LEE011 in Healthy Subjects With Normal Hepatic Function and Subjects With Impaired Hepatic Function.
The purpose of this study is to evaluate the pharmacokinetics (PK), safety and tolerability of a single oral dose of LEE011 in subjects with varying degrees of impaired hepatic function (based on Child-Pugh classification) as compared to demographically-matched control subjects with normal hepatic function.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT04136444 -
A Pharmacokinetic Study of Padsevonil in Study Participants With Either Normal or Moderately Impaired Hepatic Function
|
Phase 1 | |
| Completed |
NCT02135302 -
A Phase 1, Open-Label Study to Assess the Single-Dose Pharmacokinetics of Eravacycline in Subjects With Impaired Hepatic Function and Healthy Subjects
|
Phase 1 | |
| Completed |
NCT01764776 -
Effect of Hepatic Impairment on LDE225..
|
Phase 1 | |
| Completed |
NCT01950481 -
Effect of Hepatic Impairment on LDK378 Pharmacokinetics
|
Phase 1 | |
| Completed |
NCT00398424 -
Evaluating Patients With Impaired Hepatic Function
|
Phase 1 | |
| Recruiting |
NCT05259085 -
Study of ALXN2050 in Participants With Hepatic Impairment
|
Phase 1 | |
| Completed |
NCT04823702 -
Study of Aldafermin (NGM282) in Participants With Impaired Hepatic Function
|
Phase 1 |